0 XP   0   0   0

Aclaris Therapeutics Inc










Financial Health of Aclaris Therapeutics Inc




Comparing to competitors in the Diagnostics & Research industry




  Industry Rankings  


Aclaris Therapeutics Inc
Buy, Hold or Sell?

Should you buy, hold or sell Aclaris Therapeutics Inc?

I guess you are interested in Aclaris Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Aclaris Therapeutics Inc

Let's start. I'm going to help you getting a better view of Aclaris Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Aclaris Therapeutics Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Aclaris Therapeutics Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Aclaris Therapeutics Inc. The closing price on 2022-12-02 was $16.64 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Aclaris Therapeutics Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Aclaris Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aclaris Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -104.9% means that $-1.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aclaris Therapeutics Inc:

  • The MRQ is -104.9%. The company is making a huge loss. -2
  • The TTM is -1,065.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-104.9%TTM-1,065.2%+960.3%
TTM-1,065.2%YOY-1,180.5%+115.3%
TTM-1,065.2%5Y-1,461.3%+396.0%
5Y-1,461.3%10Y-937.8%-523.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-104.9%-7.3%-97.6%
TTM-1,065.2%-4.9%-1,060.3%
YOY-1,180.5%0.5%-1,181.0%
5Y-1,461.3%-5.8%-1,455.5%
10Y-937.8%-3.4%-934.4%
1.1.2. Return on Assets

Shows how efficient Aclaris Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • -7.5% Return on Assets means that Aclaris Therapeutics Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aclaris Therapeutics Inc:

  • The MRQ is -7.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.5%TTM-8.1%+0.6%
TTM-8.1%YOY-12.7%+4.6%
TTM-8.1%5Y-14.5%+6.4%
5Y-14.5%10Y-13.5%-1.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.5%-0.5%-7.0%
TTM-8.1%-0.4%-7.7%
YOY-12.7%0.2%-12.9%
5Y-14.5%-0.8%-13.7%
10Y-13.5%-0.8%-12.7%
1.1.3. Return on Equity

Shows how efficient Aclaris Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • -9.1% Return on Equity means Aclaris Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aclaris Therapeutics Inc:

  • The MRQ is -9.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.1%TTM-9.9%+0.9%
TTM-9.9%YOY-19.5%+9.6%
TTM-9.9%5Y-21.3%+11.4%
5Y-21.3%10Y-16.7%-4.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.1%0.7%-9.8%
TTM-9.9%0.3%-10.2%
YOY-19.5%0.6%-20.1%
5Y-21.3%-1.3%-20.0%
10Y-16.7%-1.8%-14.9%

1.2. Operating Efficiency of Aclaris Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aclaris Therapeutics Inc is operating .

  • Measures how much profit Aclaris Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • An Operating Margin of -109.8% means the company generated $-1.10  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aclaris Therapeutics Inc:

  • The MRQ is -109.8%. The company is operating very inefficient. -2
  • The TTM is -1,066.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-109.8%TTM-1,066.5%+956.7%
TTM-1,066.5%YOY-1,183.4%+117.0%
TTM-1,066.5%5Y-1,471.2%+404.8%
5Y-1,471.2%10Y-943.7%-527.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-109.8%0.3%-110.1%
TTM-1,066.5%-1.8%-1,064.7%
YOY-1,183.4%1.1%-1,184.5%
5Y-1,471.2%-2.5%-1,468.7%
10Y-943.7%-1.6%-942.1%
1.2.2. Operating Ratio

Measures how efficient Aclaris Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 2.10 means that the operating costs are $2.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 2.098. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.172. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.098TTM12.172-10.074
TTM12.172YOY9.579+2.592
TTM12.1725Y13.370-1.199
5Y13.37010Y8.701+4.670
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0981.329+0.769
TTM12.1721.234+10.938
YOY9.5791.234+8.345
5Y13.3701.103+12.267
10Y8.7011.031+7.670

1.3. Liquidity of Aclaris Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 12.54 means the company has $12.54 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 12.535. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.220. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.535TTM12.220+0.315
TTM12.220YOY10.212+2.008
TTM12.2205Y8.426+3.794
5Y8.42610Y12.277-3.851
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ12.5352.412+10.123
TTM12.2202.617+9.603
YOY10.2122.767+7.445
5Y8.4262.626+5.800
10Y12.2772.837+9.440
1.3.2. Quick Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • A Quick Ratio of 21.99 means the company can pay off $21.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 21.985. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 19.048. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.985TTM19.048+2.937
TTM19.048YOY15.977+3.071
TTM19.0485Y13.317+5.731
5Y13.31710Y20.515-7.198
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ21.9851.321+20.664
TTM19.0481.454+17.594
YOY15.9771.515+14.462
5Y13.3171.553+11.764
10Y20.5151.530+18.985

1.4. Solvency of Aclaris Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aclaris Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aclaris Therapeutics Inc to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.18 means that Aclaris Therapeutics Inc assets are financed with 17.9% credit (debt) and the remaining percentage (100% - 17.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.179. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.187. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.179TTM0.187-0.009
TTM0.187YOY0.285-0.097
TTM0.1875Y0.262-0.074
5Y0.26210Y0.355-0.093
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1790.404-0.225
TTM0.1870.404-0.217
YOY0.2850.433-0.148
5Y0.2620.453-0.191
10Y0.3550.442-0.087
1.4.2. Debt to Equity Ratio

Measures if Aclaris Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 21.7% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.217. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.232. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.217TTM0.232-0.014
TTM0.232YOY0.441-0.210
TTM0.2325Y0.396-0.165
5Y0.39610Y0.331+0.065
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2170.598-0.381
TTM0.2320.620-0.388
YOY0.4410.672-0.231
5Y0.3960.753-0.357
10Y0.3310.741-0.410

2. Market Valuation of Aclaris Therapeutics Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aclaris Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
  • A PE ratio of -52.60 means the investor is paying $-52.60 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is -55.607. Company is losing money. -2
  • The MRQ is -52.600. Company is losing money. -2
  • The TTM is -50.404. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-55.607MRQ-52.600-3.008
MRQ-52.600TTM-50.404-2.196
TTM-50.404YOY-53.099+2.695
TTM-50.4045Y-31.851-18.553
5Y-31.85110Y-43.001+11.150
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-55.607-1.994-53.613
MRQ-52.600-2.312-50.288
TTM-50.404-4.930-45.474
YOY-53.099-0.548-52.551
5Y-31.851-1.611-30.240
10Y-43.001-1.973-41.028
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Aclaris Therapeutics Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is -1,806.039. Very Bad. -2
  • The TTM is -243.412. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-1,806.039TTM-243.412-1,562.627
TTM-243.412YOY142.734-386.147
TTM-243.4125Y43.259-286.671
5Y43.25910Y-211.235+254.494
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,806.039-0.052-1,805.987
TTM-243.4120.036-243.448
YOY142.7340.113+142.621
5Y43.2590.023+43.236
10Y-211.2350.023-211.258

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aclaris Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 4.77 means the investor is paying $4.77 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is 5.047. Seems overpriced? -1
  • The MRQ is 4.774. Neutral. Compare to industry.
  • The TTM is 5.003. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD5.047MRQ4.774+0.273
MRQ4.774TTM5.003-0.229
TTM5.003YOY9.242-4.239
TTM5.0035Y5.007-0.004
5Y5.00710Y6.186-1.179
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD5.0472.021+3.026
MRQ4.7742.205+2.569
TTM5.0033.188+1.815
YOY9.2424.346+4.896
5Y5.0073.414+1.593
10Y6.1863.056+3.130
2. Total Gains per Share

2.4. Latest News of Aclaris Therapeutics Inc

Does Aclaris Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Aclaris Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-08
14:25
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue EstimatesRead

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aclaris Therapeutics Inc.

3.1. Institutions holding Aclaris Therapeutics Inc

Institutions are holding 96.199% of the shares of Aclaris Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30Wellington Management Company LLP7.35130.01384901263-828990-14.4669
2022-06-30VR Adviser, LLC6.845411.4991456396200
2022-06-30RA Capital Management, LLC6.59721.637243984532580645141.9647
2022-06-30Bvf Inc5.96442.681397654300
2022-06-30Rock Springs Capital Management LP5.89031.59553927149621151.6071
2022-06-30Vanguard Group Inc4.22020.00112813685848653.11
2022-06-30Foresite Capital Management IV, LLC4.211710.55512808034-91000-3.139
2022-06-30COMMODORE CAPITAL LP3.61577.1152410622959744.1464
2022-06-30Orbimed Advisors, LLC3.4880.5882232550074560047.1929
2022-06-30Holocene Advisors, LP3.09110.1738206091800
2022-06-30Point72 Asset Management, L.P.2.60070.10211733900-543200-23.8549
2022-06-30LAURION CAPITAL MANAGEMENT LP2.15990.3105144007500
2022-06-30Renaissance Technologies Corp1.99440.0221329678-127900-8.7748
2022-06-30Foresite Capital Management V, LLC1.887212.2711125824300
2022-06-30FMR Inc1.86330.00171242308289582.3866
2022-06-30State Street Corporation1.84520.001123024114685113.5548
2022-06-30Deutsche Bank AG1.76190.00921174701-292402-19.9306
2022-06-30TCG Crossover Management, LLC1.71736.7893114493900
2022-06-30Great Point Partners LLC1.62443.626108300014055514.9139
2022-06-30Geode Capital Management, LLC1.43570.00295721611082513.0938
Total 70.165358.994746780430+2112896+4.5%

3.2. Funds holding Aclaris Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-10-31Vanguard Total Stock Mkt Idx Inv2.68030.0024178697900
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr2.68030.00271786979248401.4097
2022-10-31iShares Russell 2000 ETF2.16370.0423144259647120.3277
2022-07-31Biotech Growth Ord1.84264.1002122850000
2022-10-31Vanguard Extended Market Index Investor1.06680.013371127668620.9741
2022-10-31iShares Russell 2000 Growth ETF0.77130.0833514221-2412-0.4669
2022-08-31Fidelity® Small Cap Index0.68980.03945992178351.7331
2022-10-31iShares Biotechnology ETF0.59410.076639607718960.481
2022-09-30Fidelity® Select Biotechnology0.46270.0955308483-127106-29.1803
2022-09-30State St Russell Sm/Mid Cp® Indx NL Cl C0.45640.0161304300205007.2234
2022-09-30Fidelity® VIP Growth Initial0.41830.067727890000
2022-09-30Fidelity® Extended Market Index0.38570.014525718500
2022-09-30State St Russell Sm Cap® Indx NL Cl C0.35560.0451237084210769.757
2022-09-30Hartford Small Company Y0.35550.606623699700
2022-09-30Fidelity® Capital Appreciation0.3270.069321800000
2022-10-31Schwab US Small-Cap ETF™0.32090.024621396600
2022-09-30Hartford Small Cap Growth HLS IA0.29050.45193663-71010-26.8293
2022-09-30NT R2000 Growth Index Fund - NL0.28870.0901192514151268.5271
2022-09-30NT R2000 Index Fund - NL0.27770.0463185125143838.4238
2022-04-30United Global Healthcare SGD Acc0.26380.39781758524670236.1611
Total 16.69176.283411128618-36596-0.3%

3.3. Insider Transactions

Insiders are holding 3.025% of the shares of Aclaris Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-10-26Andrew N SchiffSELL1454017488381
2022-10-24Andrew N SchiffSELL1461617.01514939
2022-10-17Andrew N SchiffSELL1994416.05561648
2022-10-17Joseph MonahanSELL500015.98101386
2022-10-06Andrew N SchiffSELL3783916.54588916
2022-10-04Andrew N SchiffSELL770016.01626755
2022-06-17Andrew N. SchiffSELL1956515.14
2022-04-25Neal WalkerSELL2000015.181245763
2022-04-21Neal WalkerSELL2500015.241290763
2022-04-18Joseph MonahanSELL3000016.28106386
2022-03-11Neal WalkerSELL5630315.91
2022-03-10Frank RuffoSELL1282315.55
2022-03-10Joseph MonahanSELL2716515.71
2022-02-09Joseph MonahanSELL38312.68
2021-07-13David N GordonSELL263116.98147447
2021-06-03Kamil Ali-jacksonSELL949221.96122196
2021-06-02Neal WalkerSELL3326021.641265442
2021-06-01David N GordonSELL1400023.01195992
2021-05-07Kamil Ali-jacksonSELL541623.52158618
2021-05-05Kamil Ali-jacksonSELL1500023.98158618

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aclaris Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2390.012-2063%0.659-136%-0.018-92%0.097-346%
Book Value Growth---0.072-0.007-90%0.256-128%-0.058-20%0.027-367%
Book Value Per Share--3.2973.124+6%2.251+46%2.263+46%1.794+84%
Book Value Per Share Growth---0.072-0.007-90%0.256-128%-0.058-20%0.027-367%
Current Ratio--12.53512.220+3%10.212+23%8.426+49%12.277+2%
Debt To Asset Ratio--0.1790.187-5%0.285-37%0.262-32%0.355-50%
Debt To Equity Ratio--0.2170.232-6%0.441-51%0.396-45%0.331-34%
Dividend Per Share----0%-0%-0%-0%
Eps---0.299-0.308+3%-0.305+2%-0.397+33%-0.333+11%
Eps Growth--0.0290.021+37%-0.073+349%0.076-61%0.245-88%
Gross Profit Margin--1.0001.0000%1.005-1%1.094-9%1.026-3%
Net Profit Margin---1.049-10.652+915%-11.805+1025%-14.613+1293%-9.378+794%
Operating Margin---1.098-10.665+872%-11.834+978%-14.712+1240%-9.437+760%
Operating Ratio--2.09812.172-83%9.579-78%13.370-84%8.701-76%
Pb Ratio5.047+5%4.7745.003-5%9.242-48%5.007-5%6.186-23%
Pe Ratio-55.607-6%-52.600-50.404-4%-53.099+1%-31.851-39%-43.001-18%
Peg Ratio---1806.039-243.412-87%142.734-1365%43.259-4275%-211.235-88%
Price Per Share16.640+5%15.74015.370+2%16.808-6%11.458+37%12.618+25%
Price To Total Gains Ratio-69.662-6%-65.895-41.645-37%-44.082-33%-30.894-53%-24.811-62%
Profit Growth--2.9072.129+37%-7.265+350%6.993-58%0.026+11284%
Quick Ratio--21.98519.048+15%15.977+38%13.317+65%20.515+7%
Return On Assets---0.075-0.081+8%-0.127+70%-0.145+94%-0.135+82%
Return On Equity---0.091-0.099+10%-0.195+115%-0.213+135%-0.167+84%
Revenue Growth--0.9200.208+343%0.030+2963%-0.148+116%-0.093+110%
Total Gains Per Share---0.2390.012-2063%0.659-136%-0.018-92%0.097-346%
Total Gains Per Share Growth---4.488-0.790-82%-1.213-73%-0.621-86%-1.084-76%
Usd Book Value--219838000.000208282500.000+6%150085000.000+46%150891350.000+46%119586617.647+84%
Usd Book Value Change Per Share---0.2390.012-2063%0.659-136%-0.018-92%0.097-346%
Usd Book Value Per Share--3.2973.124+6%2.251+46%2.263+46%1.794+84%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.299-0.308+3%-0.305+2%-0.397+33%-0.333+11%
Usd Price Per Share16.640+5%15.74015.370+2%16.808-6%11.458+37%12.618+25%
Usd Profit---19952000.000-20519250.000+3%-20308500.000+2%-25908950.000+30%-18754852.941-6%
Usd Revenue--19018000.0005875000.000+224%1710000.000+1012%2965800.000+541%1764705.882+978%
Usd Total Gains Per Share---0.2390.012-2063%0.659-136%-0.018-92%0.097-346%
 EOD+2 -3MRQTTM+23 -9YOY+22 -115Y+21 -1210Y+21 -12

4.2. Fundamental Score

Let's check the fundamental score of Aclaris Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-55.607
Price to Book Ratio (EOD)Between0-15.047
Net Profit Margin (MRQ)Greater than0-1.049
Operating Margin (MRQ)Greater than0-1.098
Quick Ratio (MRQ)Greater than121.985
Current Ratio (MRQ)Greater than112.535
Debt to Asset Ratio (MRQ)Less than10.179
Debt to Equity Ratio (MRQ)Less than10.217
Return on Equity (MRQ)Greater than0.15-0.091
Return on Assets (MRQ)Greater than0.05-0.075
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Aclaris Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose15.720
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets267,632
Total Liabilities47,794
Total Stockholder Equity219,838
 As reported
Total Liabilities 47,794
Total Stockholder Equity+ 219,838
Total Assets = 267,632

Assets

Total Assets267,632
Total Current Assets248,062
Long-term Assets248,062
Total Current Assets
Cash And Cash Equivalents 61,653
Short-term Investments 186,409
Net Receivables 597
Total Current Assets  (as reported)248,062
Total Current Assets  (calculated)248,659
+/- 597
Long-term Assets
Property Plant Equipment 1,145
Intangible Assets 6,992
Long-term Assets Other 2,922
Long-term Assets  (as reported)11,059
Long-term Assets  (calculated)11,059
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities19,789
Long-term Liabilities28,005
Total Stockholder Equity219,838
Total Current Liabilities
Short-term Debt 766
Accounts payable 7,667
Other Current Liabilities 19,789
Total Current Liabilities  (as reported)19,789
Total Current Liabilities  (calculated)28,222
+/- 8,433
Long-term Liabilities
Long-term Liabilities  (as reported)28,005
Long-term Liabilities  (calculated)0
+/- 28,005
Total Stockholder Equity
Retained Earnings -654,680
Accumulated Other Comprehensive Income -1,465
Total Stockholder Equity (as reported)219,838
Total Stockholder Equity (calculated)-656,145
+/- 875,983
Other
Cash and Short Term Investments 248,062
Common Stock Shares Outstanding 66,675
Liabilities and Stockholders Equity 267,632
Net Debt -60,887
Short Long Term Debt Total 766



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-31
> Total Assets 
14,207
0
17,377
0
12,223
42,087
94,076
87,270
96,092
86,071
176,085
166,210
176,808
261,391
243,509
220,622
201,819
176,176
275,566
253,183
217,239
160,416
98,297
96,812
84,999
71,902
70,784
161,399
288,046
263,494
251,211
226,527
277,976
267,632
267,632277,976226,527251,211263,494288,046161,39970,78471,90284,99996,81298,297160,416217,239253,183275,566176,176201,819220,622243,509261,391176,808166,210176,08586,07196,09287,27094,07642,08712,223017,377014,207
   > Total Current Assets 
0
0
16,334
0
10,444
39,360
86,524
86,833
95,638
85,590
138,556
157,349
175,751
234,122
200,221
192,256
171,172
145,519
179,499
156,813
137,894
145,370
83,803
82,714
70,955
57,997
57,493
134,501
241,261
205,782
205,032
190,881
259,354
248,062
248,062259,354190,881205,032205,782241,261134,50157,49357,99770,95582,71483,803145,370137,894156,813179,499145,519171,172192,256200,221234,122175,751157,349138,55685,59095,63886,83386,52439,36010,444016,33400
       Cash And Cash Equivalents 
9,588
0
10,757
0
9,853
25,419
9,851
13,131
31,815
17,796
30,171
23,677
32,708
60,055
20,202
54,881
46,035
26,590
57,019
34,197
31,654
29,898
35,937
53,992
32,587
23,643
22,063
35,267
113,447
53,602
27,349
36,342
68,264
61,653
61,65368,26436,34227,34953,602113,44735,26722,06323,64332,58753,99235,93729,89831,65434,19757,01926,59046,03554,88120,20260,05532,70823,67730,17117,79631,81513,1319,85125,4199,853010,75709,588
       Short-term Investments 
3,736
0
5,373
0
0
12,986
75,017
72,115
62,195
66,246
107,051
129,741
137,789
167,793
173,655
132,096
118,569
107,681
110,953
102,558
83,863
61,530
39,078
25,013
35,528
29,834
32,068
93,028
118,227
144,280
164,065
143,280
180,339
186,409
186,409180,339143,280164,065144,280118,22793,02832,06829,83435,52825,01339,07861,53083,863102,558110,953107,681118,569132,096173,655167,793137,789129,741107,05166,24662,19572,11575,01712,986005,37303,736
       Net Receivables 
0
0
0
0
0
23
22
20
20
20
20
20
20
658
481
529
2,182
1,033
4,861
15,817
19,370
673
704
933
775
887
772
817
939
811
623
633
637
597
59763763362381193981777288777593370467319,37015,8174,8611,0332,182529481658202020202020222300000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,026
1,044
791
856
185
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001858567911,0441,0260000000000000000
   > Long-term Assets 
0
0
1,043
0
1,779
2,727
7,552
437
454
481
37,529
8,861
1,057
27,269
43,288
28,366
30,647
30,657
96,067
96,370
79,345
15,046
14,494
14,098
14,044
13,905
13,291
26,898
46,785
57,712
46,179
35,646
18,622
11,059
11,05918,62235,64646,17957,71246,78526,89813,29113,90514,04414,09814,49415,04679,34596,37096,06730,65730,64728,36643,28827,2691,0578,86137,5294814544377,5522,7271,77901,04300
       Property Plant Equipment 
19
0
515
0
641
761
360
417
434
461
481
706
938
1,203
2,159
2,191
4,375
4,409
4,280
4,026
4,241
2,854
2,470
2,187
2,230
1,920
1,654
1,424
1,287
1,170
1,335
1,277
1,276
1,145
1,1451,2761,2771,3351,1701,2871,4241,6541,9202,2302,1872,4702,8544,2414,0264,2804,4094,3752,1912,1591,2039387064814614344173607616410515019
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
18,504
18,504
18,504
18,504
18,504
18,504
18,504
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000018,50418,50418,50418,50418,50418,50418,5040000000000000
       Long Term Investments 
0
0
518
0
0
0
7,170
0
0
0
36,912
0
0
0
14,997
0
0
0
0
0
0
0
0
0
0
0
0
14,362
34,503
45,735
34,242
23,955
7,221
0
07,22123,95534,24245,73534,50314,36200000000000014,99700036,9120007,17000051800
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
7,367
7,349
7,330
7,311
7,292
72,951
71,459
69,781
7,217
7,199
7,180
7,161
7,142
7,123
7,105
7,086
7,067
7,048
7,030
7,011
6,992
6,9927,0117,0307,0487,0677,0867,1057,1237,1427,1617,1807,1997,21769,78171,45972,9517,2927,3117,3307,3497,3670000000000000
       Long-term Assets Other 
0
0
10
0
1,138
1,966
22
20
20
20
136
136
119
195
279
341
457
452
332
2,381
5,323
4,975
4,825
4,731
4,653
4,843
4,514
4,007
3,909
3,740
3,554
3,384
3,114
2,922
2,9223,1143,3843,5543,7403,9094,0074,5144,8434,6534,7314,8254,9755,3232,381332452457341279195119136136202020221,9661,13801000
> Total Liabilities 
370
0
38,132
0
1,427
80,205
1,555
4,059
5,852
4,949
6,595
5,921
8,664
17,132
18,247
20,150
27,616
29,848
60,442
70,930
80,009
75,141
28,385
38,637
35,633
31,145
33,134
49,105
54,231
46,913
53,870
46,328
42,224
47,794
47,79442,22446,32853,87046,91354,23149,10533,13431,14535,63338,63728,38575,14180,00970,93060,44229,84827,61620,15018,24717,1328,6645,9216,5954,9495,8524,0591,55580,2051,427038,1320370
   > Total Current Liabilities 
367
0
1,451
0
1,424
1,897
1,555
3,729
5,507
4,591
6,223
5,637
8,369
9,993
12,762
13,823
20,069
22,280
27,342
36,228
42,748
38,989
22,432
20,603
17,745
12,788
14,874
14,505
14,916
17,839
22,931
16,726
16,217
19,789
19,78916,21716,72622,93117,83914,91614,50514,87412,78817,74520,60322,43238,98942,74836,22827,34222,28020,06913,82312,7629,9938,3695,6376,2234,5915,5073,7291,5551,8971,42401,4510367
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142
142
552
591
601
868
991
642
637
624
610
591
603
625
647
669
1,386
716
741
766
7667417161,38666964762560359161062463764299186860159155214214200000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142
142
552
0
0
373
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000003730055214214200000000000000
       Accounts payable 
353
0
1,263
0
957
958
810
2,808
3,309
1,774
2,845
3,604
5,848
6,483
7,822
8,155
12,504
13,735
14,755
14,574
14,160
17,780
9,917
6,946
5,502
5,081
5,254
7,292
4,244
7,564
9,985
8,121
5,703
7,667
7,6675,7038,1219,9857,5644,2447,2925,2545,0815,5026,9469,91717,78014,16014,57414,75513,73512,5048,1557,8226,4835,8483,6042,8451,7743,3092,80881095895701,2630353
       Other Current Liabilities 
14
0
188
0
467
939
745
921
2,198
2,817
3,378
2,033
2,521
3,510
4,798
5,526
7,013
7,954
11,986
20,786
27,597
20,567
11,878
13,033
11,633
7,116
9,017
6,588
10,025
9,606
22,931
7,889
9,773
19,789
19,7899,7737,88922,9319,60610,0256,5889,0177,11611,63313,03311,87820,56727,59720,78611,9867,9547,0135,5264,7983,5102,5212,0333,3782,8172,1989217459394670188014
   > Long-term Liabilities 
0
0
36,681
0
3
78,308
0
330
345
358
372
284
295
7,139
5,485
6,327
7,547
7,568
33,100
34,702
37,261
36,152
5,953
18,034
17,888
18,357
18,260
34,600
39,315
29,074
30,939
29,602
26,007
28,005
28,00526,00729,60230,93929,07439,31534,60018,26018,35717,88818,0345,95336,15237,26134,70233,1007,5687,5476,3275,4857,139295284372358345330078,3083036,68100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,914
29,918
29,924
30,089
21
10,573
10,573
10,613
10,653
10,692
10,731
0
0
0
0
0
0000010,73110,69210,65310,61310,57310,5732130,08929,92429,91829,914000000000000000000
       Warrants
0
0
0
0
0
78,305
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000078,30500000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
330
345
358
372
284
295
0
4,936
5,778
6,998
7,019
2,637
4,235
6,788
5,673
5,404
6,912
6,766
7,195
7,240
23,541
28,217
28,707
30,572
29,235
25,640
0
025,64029,23530,57228,70728,21723,5417,2407,1956,7666,9125,4045,6736,7884,2352,6377,0196,9985,7784,93602952843723583453300000000
       Deferred Long Term Liability 
0
0
4
0
0
0
0
0
0
0
0
0
0
0
549
549
549
549
549
549
0
0
549
549
549
549
367
367
367
367
367
367
367
0
03673673673673673673675495495495490054954954954954954900000000000400
> Total Stockholder Equity
13,837
0
-20,755
0
10,796
-38,118
92,521
83,211
90,240
81,122
169,490
160,289
168,144
244,259
225,262
200,472
174,203
146,328
215,124
182,253
137,230
85,275
69,912
58,175
49,366
40,757
37,650
112,294
233,815
216,581
197,341
180,199
235,752
219,838
219,838235,752180,199197,341216,581233,815112,29437,65040,75749,36658,17569,91285,275137,230182,253215,124146,328174,203200,472225,262244,259168,144160,289169,49081,12290,24083,21192,521-38,11810,7960-20,755013,837
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
66,679,641
66,679,641111110000000000000000000000000000
   Retained Earnings Total Equity0-634,728-614,196-595,407-572,603-551,457-533,296-504,542-491,369-480,710-469,113-453,52700-329,738-292,173-253,622-220,882-189,664-159,435-136,501-118,309-103,471-90,912-79,437-68,743-55,872-42,833-38,11900000
   Accumulated Other Comprehensive Income 
0
0
-6
0
-52
1
-149
3
1
-54
-269
-249
-166
-113
-246
-328
-188
-116
-69
-49
8
-1
-66
47
15
-44
-94
-140
-184
-3
-224
-972
-1,326
-1,465
-1,465-1,326-972-224-3-184-140-94-441547-66-18-49-69-116-188-328-246-113-166-249-269-5413-1491-520-600
   Capital Surplus 
0
0
0
0
0
0
135,503
139,080
158,982
160,613
260,671
264,009
286,619
380,873
384,943
390,464
395,273
400,066
507,366
512,040
516,836
520,209
523,505
527,241
530,061
532,170
542,286
645,730
785,455
789,186
792,971
795,366
871,805
0
0871,805795,366792,971789,186785,455645,730542,286532,170530,061527,241523,505520,209516,836512,040507,366400,066395,273390,464384,943380,873286,619264,009260,671160,613158,982139,080135,503000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
0
0
21
0
38,062
85
135,396
139,146
159,073
160,681
260,528
263,936
286,681
381,091
385,177
390,819
396,064
401,295
508,968
514,064
519,309
522,361
525,505
529,652
15
535,063
542,286
648,443
785,455
789,186
197,565
795,366
871,805
875,982
875,982871,805795,366197,565789,186785,455648,443542,286535,06315529,652525,505522,361519,309514,064508,968401,295396,064390,819385,177381,091286,681263,936260,528160,681159,073139,146135,3968538,06202100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue6,761
Cost of Revenue-4,713
Gross Profit2,0482,048
 
Operating Income (+$)
Gross Profit2,048
Operating Expense-67,432
Operating Income-89,723-65,384
 
Operating Expense (+$)
Research Development43,813
Selling General Administrative23,619
Selling And Marketing Expenses-
Operating Expense67,43267,432
 
Net Interest Income (+$)
Interest Income-
Interest Expense-0
Net Interest Income-0
 
Pretax Income (+$)
Operating Income-89,723
Net Interest Income-
Other Non-Operating Income Expenses-1,142
Income Before Tax (EBT)-90,865-88,581
EBIT - interestExpense = -90,865
-90,865
-90,865
Interest Expense0
Earnings Before Interest and Taxes (ebit)-90,865-90,865
Earnings Before Interest and Taxes (ebitda)-89,942
 
After tax Income (+$)
Income Before Tax-90,865
Tax Provision-0
Net Income From Continuing Ops-90,865-90,865
Net Income-90,865
Net Income Applicable To Common Shares-90,865
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses72,145
Total Other Income/Expenses Net-1,1421,142
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ALFAVIO.BSE
1 minute ago

I found you a Death Cross on the daily chart of ALFAVIO.BSE.

ALFAVIO.BSE Daily Candlestick Chart
AJMERA.BSE
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AJMERA.BSE.

AJMERA.BSE Daily Candlestick Chart
HCM.LSE
4 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HCM.LSE.

HCM.LSE Daily Candlestick Chart
DOCS.LSE
8 minutes ago

I found you a Death Cross on the daily chart of DOCS.LSE.

DOCS.LSE Daily Candlestick Chart
RMAP.LSE
9 minutes ago

I found you a Death Cross on the daily chart of RMAP.LSE.

RMAP.LSE Daily Candlestick Chart
CPH2.LSE
9 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of CPH2.LSE.

CPH2.LSE Daily Candlestick Chart
ABF.LSE
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ABF.LSE.

ABF.LSE Daily Candlestick Chart
DOM.LSE
12 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DOM.LSE.

DOM.LSE Daily Candlestick Chart
DNLM.LSE
12 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DNLM.LSE.

DNLM.LSE Daily Candlestick Chart
FCRM.LSE
18 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of FCRM.LSE.

FCRM.LSE Daily Candlestick Chart
XLPS.LSE
21 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XLPS.LSE.

XLPS.LSE Daily Candlestick Chart
PHGP.LSE
22 minutes ago

I found you a Death Cross on the daily chart of PHGP.LSE.

PHGP.LSE Daily Candlestick Chart
EMLI.LSE
24 minutes ago

I found you a Golden Cross on the daily chart of EMLI.LSE.

EMLI.LSE Daily Candlestick Chart
SLVR.LSE
25 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SLVR.LSE.

SLVR.LSE Daily Candlestick Chart
GBAL.TO
25 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GBAL.TO.

GBAL.TO Daily Candlestick Chart
ACC.BSE
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ACC.BSE.

ACC.BSE Daily Candlestick Chart
VRL.BSE
42 minutes ago

I found you a Golden Cross on the daily chart of VRL.BSE.

VRL.BSE Daily Candlestick Chart
CANDOUR.BSE
42 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CANDOUR.BSE.

CANDOUR.BSE Daily Candlestick Chart
VMUK.LSE
53 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VMUK.LSE.

VMUK.LSE Daily Candlestick Chart
YGEN.LSE
54 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of YGEN.LSE.

YGEN.LSE Daily Candlestick Chart
GROC.LSE
54 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GROC.LSE.

GROC.LSE Daily Candlestick Chart
HMAD.LSE
55 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HMAD.LSE.

HMAD.LSE Daily Candlestick Chart
XSLR.LSE
55 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XSLR.LSE.

XSLR.LSE Daily Candlestick Chart
0HA0.LSE
56 minutes ago

I found you a Golden Cross on the daily chart of 0HA0.LSE.

0HA0.LSE Daily Candlestick Chart